Keys to the Cure: Will the Microbiome Live Up to the Hype?

“The microbiome” is everywhere in the press and fast-increasing resources are devoted to it in labs worldwide. Biotechs are busy getting microbiome-modifying compounds of all kinds to the clinic while academics generate eye-watering amounts of genomic and metabolomic data.

But when will drugs and other products come out of all those efforts? The number of key phase Ib and phase II read-outs will reach an inflexion point in 2020, will pharma and the investor community adopt those projects more widely? And in the transition from lab to clinic to drug-on-market, can this new frontier learn from those who have gone before? Panelists will address these questions and more.